Monday, 18 April, 2016 - 12:51
New CEO aims to grow Perkins subsidiary
Young medical entrepreneur Michael Winlo has returned from New York with plans to expand a unique clinical testing business in Nedlands.
Dr Michael Winlo, chief executive of Emerald Clinics since August 2019, was chief executive of Linear Clinical Research for 3 years and remained on the board from July 2019 when he stepped down from the CEO role to lead a startup company in digital health innovation. Linear Clinical Research is the clinical trials arm of the Harry Perkins Institute of Medical Research.
He was a co-founder of medical device startup Cerulean Medical in 2007, and spent five years in the US growing the health practice of data analysis firm Palantir Technologies.
Dr Winlo holds a Bachelor of Medicine and Surgery from the University of Western Australia, and an MBA from the Stanford Graduate School of Business.
Rank | Company | # | |
---|---|---|---|
117th | ![]() |
Emyria | $4.82m |
118th | ![]() |
Adveritas | $4.76m |
119th | - | HITIQ | $4.75m |
120th | ![]() |
Harvest Technology Group | $4.38m |
Rank | Company | 1 Yr | 5 Yr |
---|---|---|---|
1424th | VRX Silica">VRX Silica | -45.28% | -12.17% |
1425th | RMA Global">RMA Global | -45.48% | -35.15% |
1426th | Emyria">Emyria | -45.7% | 0% |
1427th | Strike Resources">Strike Resources | -45.75% | -9.14% |
1428th | Next Science">Next Science | -45.84% | -43.04% |
![]() |
NEWS: Tagged in Board moves January 23, 2025 | 23 Jan 2025 |
![]() |
NEW ROLE: Chief Scientific Officer, Emyria | 23 Jan 2025 |
![]() |
NEW ROLE: Non-Executive Director, Dorsavi | 25 Jul 2024 |
![]() |
NEW ROLE: Non-Executive Director, Nanoveu | 28 Mar 2023 |
![]() |
NEWS: Tagged in Healthtech banks on rising numbers | 07 Nov 2022 |
Young medical entrepreneur Michael Winlo has returned from New York with plans to expand a unique clinical testing business in Nedlands.
SPECIAL REPORT: Former mining boss Charlie Bass and surgeon Peter Santa Maria are among the growing number of people in Western Australia looking to make innovation a commercial reality.
Medical not-for-profit company Linear Clinical Research was among a diverse group of businesses to win plaudits at the recent WA Industry and Export Awards.
A Perth clinical trials company has introduced cloud-based technology to accelerate the development of drug therapies.
Nedlands-based Linear Clinical Research has won the national Business Services Award at the Australian Export Awards this week, with the judges noting its impressive growth in US projects and ability to leverages advantages in the domestic market to underpin its export success.
Our weekly appointment wrap includes Scott Jones, Terry Waldron, Reg Howard-Smith, David Buckingham, Philip Mirams, Colin Pavlovich, Ken Michael, Lee Broomhall, Kelly Howlett, Tim Youe, Joshua Byrne, David Templeman, Anne Banks-McAllister, Peter Snowsill, Martin Hirsch, Michael Winlo, Charles Fear, Patrick Beilby, Biljana Radulovic, Hector West, Matthew Seabrook, Arash Kalani, Simon Pigliardo, Kathy Reid, Melissa Joyce, Nada Raphael, Fredrick Riebeling, Gina Nofal, and Nicola Jansen.
Medicinal cannabis research company Emerald Clinics has boosted its management team with the appointment of Michael Winlo as chief executive, ahead of an expected IPO later this year.
With mainstream acceptance for cannabinoid medicines growing, Emerald Clinics has found value in building clinical evidence of its use.
Perth companies Emerald Clinics and Little Green Pharma are seeking to raise up to $18 million ahead of stock market listings as they pursue very different strategies in the medicinal cannabis market.
The state government has appointed an industry reference group to develop a growth plan for WA’s health and medical life sciences sector to be chaired by Peter Klinken.
Emerald Clinics and Little Green Pharma have both completed their initial public offerings ahead of stock market listings this month, with Emerald getting ready for its ASX debut tomorrow.
Perth’s largest drug testing company plans to nearly double capacity as WA attracts attention from global pharmaceutical companies.
Shares in Perth-based medicinal cannabis aspirant Emyria were up as much as 21 per cent after the business revealed a $5 million backing from Andrew Forrest’s investment business, Tattarang.
Andrew Forrest-backed Emyria is slated to start human clinical trials within weeks for a cannabinoid drug to treat psychological distress.
The commercial side of life sciences may have reached a critical mass in WA.
Our board moves wrap includes Andrew Metcalfe, George Lazarou, María Claudia Pohl Ibáñez, Christopher Chalwell, Michael Winlo, Brett Crowley, Erlyn Dawson, and Aaron Brinkworth.
Today’s board moves wrap includes Michael Winlo, Greg Hutchinson, Stuart Mathews, Dennis Wilkins, Felicity Gooding, Matthew Horgan, Nitin Tyagi, Kaitlin Smith and Mark Pitts.
Access to our data for Michael Winlo is only available to paid subscribers with Data & Insights access.
Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.
Michael Winlo is linked to 8 organisations which are included in 3 lists - Public Companies - non WA, Not For Profit Businesses and Public Companies - Industrial WA.
To see the data you will need to Subscribe.